Drug Search Results
More Filters [+]

STAT6 Degrader - Nurix

Alternative Names: STAT6 Degrader - Nurix
Latest Update: None
Latest Update Note: None

Product Description

Preclinical data from our STAT6 degraders show that targeted degradation of this key transcription factor provides a rapidly acting and potent blockade of signaling. We anticipate nominating a clinical candidate from this advanced preclinical program in the coming twelve months. (Sourced from: https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-extension-strategic-collaboration-0)

Mechanisms of Action: STAT6 Degrader

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for STAT6 Degrader - Nurix

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Inflammation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title